It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.
Tyrosine kinase inhibitors (TKIs) remain the backbone of systematic therapy for advanced …

Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause
tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) …

Abstract Background Cancer‐associated fibroblasts (CAFs) play an important role in the
induction of chemo‐resistance. This study aimed to clarify the mechanism underlying CAF …

Abstract ENO1 (α-enolase) expression is significantly correlated with reduced survival and
poor prognosis in many cancer types, including lung cancer. However, the function of ENO1 …

Cancer cells are known to be glycolytic, driving increased glucose consumption and its
conversion to lactate. This process modulates the tumor microenvironment (TME). In the …

The global burden of hepatocellular carcinoma (HCC), one of the frequent causes of cancer-
related deaths worldwide, is rapidly increasing partly due to the limited treatment options …

Background The role of tumor necrosis factor alpha (TNF-α) in targeted therapy for
hepatocellular carcinoma (HCC) remains largely unknown. The current study aimed to …

Molecular targeted agents, such as sorafenib, remain the only choice of an antitumor drug
for the treatment of advanced hepatocellular carcinoma (HCC). The Notch signaling …

A characteristic shared by most frequent types of primary liver cancer, ie, hepatocellular
carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent …